[Home ] [Archive]   [ فارسی ]  
:: Volume 21, Issue 2 (Iranian Journal of Ophthalmology 2009) ::
2009, 21(2): 13-18 Back to browse issues page
Central Retinal Artery Perfusion following 0.1 ml Intravitreal Injection of Bevacizumab
Hossein Nazari Dr. *, Mehdi ModarresZadeh Dr., Mohsen Bahmani-Kashkouli Dr., Masoud Naseripour Dr., Mohammad-Mehdi Parvaresh Dr., Paridokht Nazari
, h01nazari@yahoo.com
Abstract:   (20796 Views)

Purpose: To study the pattern of perfusion of central retinal artery (CRA) after 0.1 ml intravitreal injection of bevacizumab to verify the need for any maneuver to decrease the intraocular pressure (IOP) including anterior chamber paracentesis (ACP)

Methods: This is a prospective, interventional, noncomparative case series. Patients receiving intravitreal injection of bevacizumab for choroidal neovascularization (CNV) secondary to age-related macular degeneration, diabetic macular edema and retinal veno-occlusive diseases were included in the study. Each eye received 0.1 ml intravitreal injection of bevacizumab and the status of perfusion of CRA and its pulsation was monitored by indirect ophthalmoscopy until cessation of visible pulsation. Main outcome measures were patency of CRA, its pulsation and time from injection to cessation of pulsation.

Results: Seventy seven eyes of 70 patients were studied. At first ophthalmoscopy 30 seconds after injection, CRA was open in all cases with or without pulsation. CRA occlusion was not observed in any case. In 20 eyes (26%) CRA was patent without pulsation. In 57 eyes (74%) CRA pulsation was detected and this visible pulsation of CRA stopped within an average time of 167±99 seconds (range: 30-480 seconds). From 17 eyes which had significant vitreous reflux, only 6 eyes had CRA pulsation which stopped in a mean time of 80±36 seconds. There was a significant difference between pulsation duration in patients with and without vitreous reflux (Mann-Whitney U test, P=0.005). Absence of postinjection vitreous reflux was a risk factor for CRA pulsation after intravitreal injection of 0.1 ml of bevacizumab (relative risk: 2.41, 95% CI: 1.25-4.62).

Conclusion: Considering the absence of CRA closure and the short time needed for the cessation of pulsation after intravitreal injection of 0.1 ml bevacizumab, no treatment including ACP is warranted before or after such injections in nonglaucomatous eyes. Indirect ophthalmoscopy is a noninvasive useful maneuver to ascertain patency of CRA after intravitreal injections.


Iranian Journal of Ophthalmology 200921(2):13-18 © 2009 by the Iranian Society of Ophthalmology
Keywords: Intravitreal Injection, Central Retinal Artery, Intraocular Pressure
Full-Text [PDF 63 kb]   (4070 Downloads)    
Type of Study: Original | Subject: General
Send email to the article author

Add your comments about this article
Your username or Email:


XML     Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Nazari H, ModarresZadeh M, Bahmani-Kashkouli M, Naseripour M, Parvaresh M, Nazari P. Central Retinal Artery Perfusion following 0.1 ml Intravitreal Injection of Bevacizumab. Iranian Journal of Ophthalmology. 2009; 21 (2) :13-18
URL: http://irjo.org/article-1-226-en.html

Volume 21, Issue 2 (Iranian Journal of Ophthalmology 2009) Back to browse issues page
مجله چشم پزشکی ایران Iranian Journal of Ophthalmology
Persian site map - English site map - Created in 0.05 seconds with 31 queries by YEKTAWEB 4071